Search for Clinical Trial Results
Oligoastrocytoma - 83 Studies Found
Status | Study |
Terminated |
Study Name: Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Condition:
|
Not yet recruiting |
Study Name: Phase II Pediatric Study With Dabrafenib in HGG Patients Condition:
|
Terminated |
Study Name: 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas Condition:
|
Not yet recruiting |
Study Name: Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children Condition:
|
Recruiting |
Study Name: Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Condition:
Date: 2015-08-18 Interventions: Drug: Palbociclib Palbociclib will be administered orally at a dose of 125 mg/day, until disease progres |
Completed |
Study Name: Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Condition:
Date: 2006-08-08 Interventions: Drug: Temozolomide p.o.(by mouth), 150 mg/m2/d x days 1-7 |
Completed |
Study Name: Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Condition:
Date: 2013-04-29 Interventions: Drug: Temozolomide Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 2 |
Completed |
Study Name: Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas Condition:
Interventions: Biological: GAA/TT-peptide vaccine and poly-ICLC Participants will be treated with subcutaneous injectio |
Active, not recruiting |
Study Name: Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Condition: Brain and Central Nervous System Tumors Date: 2002-04-09 Interventions:
|